Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Sold by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. reduced its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 71.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,000 shares of the company's stock after selling 52,500 shares during the period. Hussman Strategic Advisors Inc. owned 0.07% of Castle Biosciences worth $420,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Covestor Ltd bought a new stake in shares of Castle Biosciences in the fourth quarter worth approximately $25,000. CWM LLC boosted its holdings in shares of Castle Biosciences by 835.0% in the first quarter. CWM LLC now owns 4,142 shares of the company's stock worth $83,000 after buying an additional 3,699 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Castle Biosciences by 1,865.8% in the first quarter. GAMMA Investing LLC now owns 4,364 shares of the company's stock worth $87,000 after buying an additional 4,142 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Castle Biosciences in the fourth quarter worth approximately $128,000. Finally, Teacher Retirement System of Texas boosted its holdings in shares of Castle Biosciences by 9.6% in the first quarter. Teacher Retirement System of Texas now owns 10,383 shares of the company's stock worth $208,000 after buying an additional 908 shares during the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have weighed in on CSTL. Lake Street Capital lowered their price target on shares of Castle Biosciences from $40.00 to $35.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. Scotiabank lowered their target price on shares of Castle Biosciences from $44.00 to $40.00 and set a "sector outperform" rating on the stock in a report on Wednesday, May 21st. Guggenheim set a $30.00 target price on shares of Castle Biosciences and gave the stock a "buy" rating in a report on Friday, March 28th. Finally, Canaccord Genuity Group lowered their target price on shares of Castle Biosciences from $42.00 to $37.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $37.00.

Castle Biosciences Stock Performance

Shares of NASDAQ CSTL traded down $0.40 during midday trading on Tuesday, reaching $16.32. 457,398 shares of the stock were exchanged, compared to its average volume of 421,760. The firm has a market cap of $471.19 million, a price-to-earnings ratio of -85.89 and a beta of 1.10. Castle Biosciences, Inc. has a twelve month low of $15.45 and a twelve month high of $35.84. The firm has a 50-day simple moving average of $18.09 and a two-hundred day simple moving average of $21.37. The company has a quick ratio of 9.19, a current ratio of 9.37 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.12). Castle Biosciences had a negative net margin of 1.46% and a positive return on equity of 3.41%. The company had revenue of $87.99 million during the quarter, compared to analyst estimates of $80.40 million. As a group, analysts anticipate that Castle Biosciences, Inc. will post 0.44 EPS for the current fiscal year.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.